← All trials
NCT07028697
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 4, 2024
- Primary completion
- Oct 31, 2025
- Completion date
- Oct 31, 2025
- First posted
- Jun 19, 2025
- Last posted
- Sep 12, 2025
- Enrollment
- 164
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nxera Pharma Korea Co., Ltd.Lead sponsor
- Nxera Pharma Korea Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.